Cargando…

WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4

Pancreatic cancer (PC) is an aggressive malignant disease. Pancreatic ductal adenocarcinoma (PDAC) is a main type of PDAC. The inhibition of aerobic glycolysis in PC cells is one of the approaches to treat PDAC. WD repeat protein 79 (WDR79) acts as a scaffold protein and is involved in several physi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Wenke, Song, Xiaoyan, Xiang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843230/ https://www.ncbi.nlm.nih.gov/pubmed/36712589 http://dx.doi.org/10.1515/med-2022-0624

Ejemplares similares

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Kapszewicz, Monika, et al.
Publicado: (2021)

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
por: Felsenstein, Matthäus, et al.
Publicado: (2022)

Screening of potential pain genes in pancreatic ductal adenocarcinoma (PDAC) based on bioinformatics methods
por: Xu, Qian, et al.
Publicado: (2023)

Neurotensin is a Versatile Modulator of In Vitro Human Pancreatic Ductal Adenocarcinoma Cell (PDAC) Migration
por: Mijatovic, Tatjana, et al.
Publicado: (2007)

PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression
por: Almeida, Palloma Porto, et al.
Publicado: (2020)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
por: Li, Ce, et al.
Publicado: (2019)

FOXO3a-SIRT6 axis suppresses aerobic glycolysis in melanoma
por: Dong, Zhen, et al.
Publicado: (2020)

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes
por: Schlitter, Anna Melissa, et al.
Publicado: (2017)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Gene Expression Characteristics of Tumor and Adjacent Non-Tumor Tissues of Pancreatic Ductal Adenocarcinoma (PDAC) In-Silico
por: Güven, Emine
Publicado: (2022)

CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer
por: Tang, Zhenyong, et al.
Publicado: (2018)

MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis
por: Lemberger, Moran, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine
por: Frappart, Pierre-Olivier, et al.
Publicado: (2020)

In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC)
por: Williams, Madison H., et al.
Publicado: (2020)

Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma
por: Penny, Hweixian Leong, et al.
Publicado: (2021)

Expression of Chosen Carcinoembryonic-Related Cell Adhesion Molecules in Pancreatic Intraepithelial Neoplasia (PanIN) Associated with Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma (PDAC)
por: Zińczuk, Justyna, et al.
Publicado: (2019)

A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC)
por: Sun, Yuqi, et al.
Publicado: (2021)

The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis
por: Kumar, Swati, et al.
Publicado: (2022)

CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation
por: Wlodarczyk, Barbara, et al.
Publicado: (2023)

Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Tao, Lianyuan, et al.
Publicado: (2016)

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study
por: Zaid, Mohamed, et al.
Publicado: (2020)

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
por: Wijnen, Rosa, et al.
Publicado: (2021)

Segmentation of pancreatic ductal adenocarcinoma (PDAC) and surrounding vessels in CT images using deep convolutional neural networks and texture descriptors
por: Mahmoudi, Tahereh, et al.
Publicado: (2022)

Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients
por: Zhang, Deyu, et al.
Publicado: (2021)

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
por: Wang, Xiuchao, et al.
Publicado: (2020)

Deep Convolutional Neural Network-Assisted Feature Extraction for Diagnostic Discrimination and Feature Visualization in Pancreatic Ductal Adenocarcinoma (PDAC) versus Autoimmune Pancreatitis (AIP)
por: Ziegelmayer, Sebastian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0mqiivlq25r4rg2k4uetltk2ac